miR-217 Promotes Cardiac Hypertrophy and Dysfunction by Targeting PTEN

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• MicroRNA Therapeutics

Background:

• Increased microRNA-217 (miR-217) expression is observed in hearts of chronic heart failure (CHF) patients.
• The specific role of miR-217 in the development of cardiac dysfunction remains largely unexplored.

Purpose of the Study:

• To investigate the functional role of miR-217 in pressure overload-induced cardiac dysfunction.
• To identify the molecular mechanisms underlying miR-217's effects on the heart.

Main Methods:

• Analysis of miR-217 expression in human CHF heart tissues and a mouse model of cardiac dysfunction (thoracic aortic constriction - TAC).
• In vivo manipulation of miR-217 expression using recombinant adeno-associated virus (rAAV9).
• Assessment of cardiac structure and function via echocardiography and pressure-volume analysis; validation of PTEN as a direct miR-217 target; in vitro fibroblast proliferation assays.

Main Results:

• miR-217 levels were elevated in both CHF patients and TAC mice.
• Overexpression of miR-217 worsened cardiac hypertrophy, fibrosis, and dysfunction in TAC mice.
• Downregulation of miR-217 ameliorated these pathological changes.
• PTEN was confirmed as a direct target, and its re-expression mitigated miR-217's adverse effects.
• Exosomes derived from cardiomyocytes containing miR-217 promoted fibroblast proliferation in vitro.

Conclusions:

• miR-217 plays a significant role in promoting cardiac hypertrophy and fibrosis.
• The miR-217/PTEN axis is a key regulator of cardiac dysfunction in response to pressure overload.
• miR-217, particularly via cardiomyocyte-derived exosomes, contributes to cardiac remodeling and suggests a potential therapeutic target for CHF.